|
Sign In to gain access to subscriptions and/or personal tools.
|
Angiology, Vol. 57, No. 5,
600-606 (2006)
DOI: 10.1177/0003319706293131
Hyperthyroidism as a Cause of Pulmonary Arterial Hypertension: A Prospective Study
Michela Armigliato, MD
Departments of Medicine, University of Padova Medical School, Padova, Italy, Rovigo and Padova, Italy
Rossella Paolini, MD
Departments of Medicine, University of Padova Medical School, Padova, Italy, Rovigo and Padova, Italy
Silvio Aggio, MD
Cardiology, Rovigo General Hospital, Rovigo University of Padova Medical School, Padova, Italy, Rovigo and Padova, Italy
Sergio Zamboni, MD
Departments of Medicine, University of Padova Medical School, Padova, Italy, Rovigo and Padova, Italy
Maria Paola Galasso, MD
Cardiology, Rovigo General Hospital, Rovigo University of Padova Medical School, Padova, Italy, Rovigo and Padova, Italy
Pietro Zonzin, MD
Cardiology, Rovigo General Hospital, Rovigo University of Padova Medical School, Padova, Italy, Rovigo and Padova, Italy
Giuseppe Cella, MD
Department of Medical and Surgical Sciences, University of Padova Medical School, Padova, Italy, Rovigo and Padova, Italy, giuseppe.cella{at}unipd.it
The authors assessed the prevalence of pulmonary arterial hypertension (PAH) in patients with hyperthyroidism and evaluated the response to treatment of the thyrotoxicosis. They assessed the pulmonary artery systolic pressure (PASP) at rest (estimated by echocardiography) in 23 consecutive patients diagnosed with hyperthyroidism due to Graves’ disease or toxic multinodular goiter. Twelve of 23 patients (52%) did not show antithyroglobulin and antithyroperoxidase antibodies. Seventeen patients were followed up for at least 9 months after achieving a stable euthyroid status. Fifteen (65%) patients demonstrated PAH at admission. Four patients were lost to follow-up; therefore they were able to evaluate 17 patients serially with echocardiography. Sixteen patients normalized their PASP value: 13 after methimazole, 2 after total thyroidectomy, and 1 after 131I treatment. In 1 patient no significant change in PASP was observed. This patient experienced an acute myocardial reinfarction during follow-up. They found a higher prevalence than that previously reported in observational studies. In addition, they demonstrated that the PAH reverses after correction of hyperthyroidism. Elevated PASP at rest on echocardiography may be considered a frequent finding of thyrotoxicosis. Moreover, the data seem not to support an autoimmune pathogenesis for PAH.
References
- Barst RJ, McGoon M, Torbicki A, et al: Diagnosis and differential assessment of pulmonary arterial hyper-tension. JACC 43: 40S-47S, 2004.[Abstract/Free Full Text]
- Farber HW, Loscalzo J: Pulmonary arterial hypertension. N Engl J Med 351: 1655-1665, 2004.[Free Full Text]
- Shimazaki M, Mitsuhashi T, Hasegawa K: Idiopathic pulmonary hypertension. Nippon Rinsho 38: 1783-1786, 1980.[Medline]
[Order article via Infotrieve]
- Thurnheer R, Jenni R, Russi EW, et al: Hyperthyroidism and pulmonary hypertension. J Internal Med 242: 185-188, 1997.
- Nakchbandi IA, Wirth JA, Inzucchi SE: Pulmonary hypertension hemodynamics restored by 131I treatment. Chest 116: 1483-1485, 1999.[Abstract/Free Full Text]
- Arroliga AC, Dweik RA, Rafanan AL: Primary pulmonary hypertension and thyroid disease. Chest 118: 1224-1225, 2000.[Free Full Text]
- Chu JW, Kao PN, Faul JL, et al: High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 122: 1668-1673, 2002.[Abstract/Free Full Text]
- Marvisi M, Brianti M, Marani G, et al: Hyperthyroidism and pulmonary hypertension. Respir Med 96: 215-220, 2002.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Yazar A, Doven O, Atis S, et al: Systolic pulmonary artery pressure and serum uric acid level in patients with hyperthyroidism. Arch Med Res 34: 35-40, 2003.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Mercé J, Ferrás S, Oltra C, et al: Cardiovascular abnormalities in hyperthyroidism: A prospective Doppler echocardiographic study. Am J Med 118: 126-131, 2005.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Biondi B, Palmieri EA, Lombardi G, et al: Effects of thyroid hormone on cardiac function. J Clin Endocrinol Metab 87: 968-974, 2002.[Abstract/Free Full Text]
- Ingbar DH: The pulmonary system in thyrotoxicosis. In: The Thyroid, ed. by Braverman LE, Utiger RD. Philadelphia: Lippincott, 2000, pp 605-627.
- Yanai-Landau H, Amital H, Bar-Dayan Y: Autoimmune aspects of primary pulmonary hypertension. Pathobiology 67: 71-75, 1995.
- Badesc DB, Wynne KM, Bonvallet S, et al: Hypothyroidism and primary pulmonary hypertension: An autoimmune pathogenetic link? Ann Intern Med 119: 44-46, 1993.[Abstract/Free Full Text]
- Curnock AL, Dweik RA, Higgins BH: High prevalence of hyperthyroidism in patients with pulmonary hypertension. Am J Med Sci 318: 289-292, 1999.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Ojamaa K, Klein I, Kenessey A: Thyroid hormone regulation of phospholamban phosphorylation in the rat heart. Endocrinology 141: 2139-2278, 2000.[Abstract/Free Full Text]
- Polikar R, Burger AG, Burger AG, et al: The thyroid and the heart. Circulation 87: 1435-1441, 1993.[Abstract/Free Full Text]
- Rich S, Braunwald E, Grossman W: Pulmonary hypertension. In: Heart Disease. A Textbook of Cardiovascular Medicine, ed. by Braunwald E. Philadelphia: Saunders, 1997, pp 780-798.
- McQuillan BM, Picard MH, Leavitt M, et al: Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 104: 2302-2797, 2001.
- Martin-Duran R, Larman M, Trugeda A, et al: Comparison of Doppler-determined elevated pulmonary arterial pressure with pressure measured at cardiac catheterization. Am J Cardiol 57: 859-863, 1986.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Klein I, Ojamaa K: Thyroid hormone and the cardiovascular system. N Engl J Med 344: 501-509, 2001.[Free Full Text]
- Guidelines Subcommittee. 1999 World Health Organization: International Society for Hypertension guidelines for the management of hypertension. J Hypertens 17: 151-183, 1999.[ISI][Medline]
[Order article via Infotrieve]
- Woeber KA: Thyrotoxicosis and the heart. N Engl J Med 327: 94-98, 1992.[Abstract]
- Moraes D, Loscalzo J: Pulmonary hypertension: Newer concepts in diagnosis and management. Clin Cardiol 20: 676-682, 1997.[ISI][Medline]
[Order article via Infotrieve]
- Cella G, Bellotto F, Tona F, et al: Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 120: 1226-1230, 2001.[Abstract/Free Full Text]
- Letizia C, Centanni M, Cesareo R, et al: Increased plasma levels of endothelin-1 in patients with hyper-thyroidism. Metabolism 44: 1239-1242, 1995.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Cesareo R, Tarabuso A, Di Benedetto M, et al: Plasmatic endothelin-1 levels in hyperthyroid patients before and after antithyroid therapy. Minerva Endocinol 25: 1-3, 2000.
- Lam HC, Lee JK, Lai KH, et al: Plasma endothelin levels are unaltered by thyroid hormone status in humans. J Cardiovasc Pharmacol 36(suppl 1): S382-S385, 2000.[ISI][Medline]
[Order article via Infotrieve]
- Diekman MJ, Harmas MP, Endert E, et al: Endocrine factors related to change in total peripheral vascular resistance after treatment of thyrotoxic and hypothyroid patients. Eur J Endocrinol 144: 339-346, 2001.[Abstract]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
|
